Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As, Imara IncfiledCriticalH Lundbeck As
Priority claimed from PCT/US2017/040160external-prioritypatent/WO2018009424A1/en
Publication of MA44025A1publicationCriticalpatent/MA44025A1/en
Publication of MA44025B1publicationCriticalpatent/MA44025B1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Medicines Containing Plant Substances
(AREA)
Abstract
La présente invention concerne des inhibiteurs de pde9, leur synthèse et leur utilisation pour le traitement de l'hyperplasie bénigne de la prostate, de la thalassémie bêta et de la drépanocytose.The present invention relates to inhibitors of pde9, their synthesis and their use for the treatment of benign prostatic hyperplasia, thalassemia beta and sickle cell disease.
MA44025A2016-07-062017-06-30
Pde9 inhibitors for the treatment of peripheral diseases
MA44025B1
(en)
LABELED INHIBITORS OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER